Peptide science for beginners: what you actually need to know before week one

By Bithi Nova· Last reviewed July 2025 · 9 min read

Six months ago I weighed 247 pounds. Today I’m at 209. I didn’t do it with willpower or a new gym membership. I started a compounded GLP-1 through a telehealth service after my PCP spent three appointments telling me to “try harder with diet and exercise.” The science behind what I was injecting, peptides, receptor agonism, dose titration, was scattered across Reddit threads and clinical abstracts. Nobody had written a plain-English walkthrough for someone starting from zero.

This is that walkthrough.

What are peptides, and why does this matter for weight loss?

Peptides are short chains of amino acids. That’s the whole definition. They’re smaller than proteins, typically under 50 amino acids long, and your body makes thousands of them naturally. What makes certain synthetic peptides medically interesting is their ability to bind specific receptors and trigger predictable physiological responses.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a 31-amino-acid peptide that mimics glucagon-like peptide-1 (GLP-1), a hormone your gut releases after eating. It binds GLP-1 receptors in the pancreas and brain, slowing gastric emptying and signaling satiety. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) ran 1,961 adults with obesity through 68 weeks of 2.4mg weekly semaglutide and found 14.9% mean body weight reduction. That’s not a lifestyle intervention number. That’s a drug number.

Tirzepatide goes further. It’s a dual GIP/GLP-1 receptor agonist, one molecule hitting two receptors. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 20.9% body weight loss at 72 weeks in the 15mg group among 2,539 participants. And retatrutide, the peptide currently in Phase 3 trials, is a triple agonist: GLP-1, GIP, and glucagon receptors simultaneously. A Phase 2 trial (Jastreboff et al., NEJM, 2023) showed 24.2% weight reduction at 48 weeks in the 12mg group, numbers that haven’t been seen in obesity medicine before.

Understanding what class of peptide you’re taking, and which receptors it hits, tells you what side effects to expect and why your dose escalation schedule exists.

How do you actually prepare for your first week?

Before you inject anything, you need four things in order: a legitimate prescription, a pharmacy source you can verify, supplies, and a plan for the first 48 hours.

The prescription. You can’t get compounded semaglutide from a 503B-outsourcing facility without a valid prescription. Telehealth services like those using compounded GLP-1 can connect you with a prescribing clinician who reviews your health history asynchronously. My process took about 48 hours from intake form to approval. Your PCP may or may not cooperate, mine didn’t, which is why I went the telehealth route.

The pharmacy source. Not all compounded peptides are equal. 503B-outsourcing facilities are registered with the FDA and operate under cGMP standards, which means sterility testing and batch records. 503A pharmacies compound per individual prescription. Both are legal; 503B has more federal oversight. Ask your telehealth provider which category their pharmacy falls under before you accept a shipment.

Supplies. You’ll need alcohol swabs, a sharps container, and a comfort level with subcutaneous injection. The needles that come with most compounded semaglutide vials are 29–31 gauge, half-inch. They go into the fat layer of your abdomen, thigh, or upper arm. The first injection is the hardest. The fifth one is nothing.

The first 48 hours. Eat light. Seriously. High-fat meals and large portions in the first day or two after injection will make nausea significantly worse. Keep meals small, low-fat, and spaced out. Have ginger tea, Zofran if your provider prescribed it, and nothing ambitious on your calendar the day after your first shot.

What does a dose escalation schedule actually look like?

The standard starting dose for compounded semaglutide is 0.25mg weekly for the first four weeks. This isn’t a therapeutic dose. It’s a tolerance-building phase. The goal is getting your GI system adapted to slower gastric emptying before you push the dose into the range where the weight loss actually happens.

Here’s a typical escalation table for semaglutide:

Week Dose (mg/week) Primary goal 1–4 0.25 Tolerance 5–8 0.5 Early efficacy 9–12 1.0 Therapeutic range 13–16 1.7 Continued titration 17+ 2.4 Maintenance (Wegovy label dose)

Your prescriber may adjust this based on how you’re tolerating each step. I spent six weeks at 0.5mg because my nausea at 1.0mg was bad enough to affect work. That’s not a failure, that’s the protocol working as designed. The label for Wegovy (semaglutide 2.4mg) explicitly allows extended time at each dose level if tolerability requires it.

For tirzepatide, starting doses are typically 2.5mg weekly, with escalation every four weeks up to a maximum of 15mg. The SURMOUNT-1 protocol used exactly that schedule.

How bad is the nausea, and what actually helps?

Nausea is the most common side effect of GLP-1 receptor agonists. In STEP 1, 44% of participants in the semaglutide group reported nausea, versus 16% on placebo. Most cases were mild to moderate and peaked in the early titration phase. That said, 4.5% discontinued due to GI adverse events.

My first month was rough. Not debilitating, but I lost about a week of normal eating. The things that actually helped:

Eat before the shot, not after. A small meal two hours before injection gave my stomach something to work with. Eating a large meal after the shot, especially anything high in fat, made things noticeably worse.

Ginger works. A 2012 meta-analysis (Viljoen et al., Nutrition Journal) covering six randomized controlled trials found ginger significantly reduced nausea severity across several clinical contexts. It’s not a cure, but 250mg ginger capsules with meals genuinely took the edge off.

Timing the injection matters. Many people do better injecting at night so peak nausea happens during sleep. I switched from morning to evening injections around week three and noticed a real difference.

If nausea is severe enough to cause vomiting or you can’t keep food down for more than 24 hours, contact your prescriber. Ondansetron (Zofran) is commonly prescribed alongside GLP-1 therapy for exactly this reason.

How do you measure progress without obsessing over the scale?

Weight is one data point, not the only one. I weigh myself weekly, same day, same time, after waking. That’s it. Daily weigh-ins on a GLP-1 are a psychological trap, water retention, glycogen fluctuations, and constipation (another common side effect) will move the scale around by 2–4 pounds in ways that have nothing to do with fat loss.

Track these four things instead:

Waist circumference. Measured at the navel, weekly. This captures visceral fat reduction that the scale may lag on. The American Heart Association considers waist circumference a better predictor of cardiometabolic risk than BMI.

Photos. Every four weeks, same lighting, same angle. You will not see weekly changes. You will absolutely see four-week changes.

HbA1c and fasting glucose (if your provider orders labs). Semaglutide was originally developed as a diabetes medication. Even in people without diabetes, GLP-1 therapy improves insulin sensitivity. The SUSTAIN-6 trial (Marso et al., NEJM, 2016) showed significant HbA1c reduction alongside cardiovascular benefit in type 2 diabetic patients.

Energy and hunger on a 1–10 scale. Keep a simple note. The appetite suppression often precedes visible weight loss by weeks. Noticing that you’re genuinely not hungry at 2pm when you used to be ravenous is meaningful progress, even if the scale hasn’t moved.

After six months on compounded GLP-1, I’m down 38 pounds. My waist went from 44 inches to 38 inches. My fasting glucose dropped from 108 to 92. The scale tells part of the story.

What’s the difference between semaglutide, tirzepatide, and retatrutide?

Each generation of GLP-1 class peptides adds receptor targets and, correspondingly, adds efficacy.

Peptide Receptors Max trial weight loss Status Semaglutide GLP-1 14.9% (STEP 1, 68 weeks) FDA approved (brand) / compounded available Tirzepatide GLP-1 + GIP 20.9% (SURMOUNT-1, 72 weeks) FDA approved (brand) / compounded available Retatrutide GLP-1 + GIP + glucagon 24.2% (Phase 2, 48 weeks) Phase 3 trials ongoing

Retatrutide’s glucagon receptor activity is what separates it mechanically. Glucagon normally raises blood glucose, but in a tri-agonist context, the GLP-1 component appears to counteract that effect while the glucagon agonism adds to energy expenditure and fat oxidation. The Phase 2 data (Jastreboff et al., NEJM, 2023) is striking: 24.2% mean weight loss at 48 weeks in the 12mg group, which is roughly what bariatric surgery produces in the same timeframe.

Retatrutide is not available commercially yet. It is not currently available as a compounded peptide through legitimate 503B pharmacies. If someone is selling you “retatrutide” right now, ask hard questions about its origin.

For most people starting today, the practical choice is between semaglutide and tirzepatide. Your prescriber should help you choose based on cost, your metabolic profile, and your tolerance history.

Frequently asked questions

Is compounded semaglutide the same thing as Ozempic or Wegovy?

Compounded semaglutide contains the same active ingredient, semaglutide, but it’s not manufactured by Novo Nordisk and it’s not FDA-approved as a finished drug product. It’s legally produced by 503A or 503B compounding pharmacies under the Federal Food, Drug, and Cosmetic Act. The FDA has specific guidance on compounded semaglutide permissibility that has shifted as the brand shortage status has changed, check FDA.gov for current status.

Do I need to refrigerate my compounded peptide vial?

Yes. Compounded semaglutide vials should be stored at 36–46°F (2–8°C) before first use. After opening, most compounding pharmacies recommend use within 28–30 days. Keep it away from light and don’t freeze it. Your pharmacy’s label instructions take precedence over any general guidance.

What happens if I miss a dose?

If you miss a dose and your next scheduled dose is more than 48 hours away, inject as soon as you remember. If it’s within 48 hours of your next scheduled dose, skip the missed one and resume your regular schedule. Don’t double up. This follows the Wegovy prescribing information, which is the closest reference standard for compounded semaglutide dosing guidance.

Will I lose muscle mass on a GLP-1?

Some muscle loss occurs with any significant calorie deficit. A 2023 analysis (Wilding et al., Diabetes, Obesity and Metabolism) looking at body composition data from semaglutide trials found that lean mass loss occurred but was proportional to overall weight loss, consistent with other weight-loss interventions. Resistance training and adequate protein intake (1.2–1.6g per kg of body weight) are the standard mitigations. This is worth discussing with your prescriber, especially if you’re already lean.

How much does compounded semaglutide cost compared to the brand?

Wegovy has a list price of approximately $1,349/month without insurance. Compounded semaglutide through telehealth providers runs roughly $150–400/month depending on dose and provider. I pay significantly less than the brand price. The cost difference is why most people without comprehensive insurance coverage end up in the compounded market.

Can I drink alcohol while on semaglutide?

There’s no absolute contraindication, but GLP-1 therapy slows gastric emptying, which changes how quickly alcohol is absorbed. Many people also report reduced interest in alcohol on GLP-1 therapy, which may be a dopaminergic effect. The practical issue is that alcohol is high-calorie, dehydrating, and will worsen nausea if you drink close to your injection day. Keep it minimal, especially in the first few months.

When should I expect to see real results?

Most people see some appetite suppression within the first one to two weeks. Noticeable scale weight changes typically start by weeks four to eight at the 0.5mg dose. Meaningful loss, five percent of body weight or more, usually happens by week twelve for people who are tolerating their dose and eating in a modest deficit. Results vary significantly by individual, starting weight, dose level, and adherence. Six months is a more realistic window for evaluating whether the therapy is working for you.

Sources

1. Wilding, J.P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff, A.M., et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Jastreboff, A.M., et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
4. Marso, S.P., et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” New England Journal of Medicine, 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
5. Viljoen, E., et al. “A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting.” Nutrition Journal, 2014. https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-20
6. U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
7. Novo Nordisk. “Wegovy (semaglutide) Prescribing Information.” https://www.novo-pi.com/wegovy.pdf